Endo Pharmaceuticals Inc, a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc announced the closing of the license agreement granting Endo the exclusive rights to market Vernalis's Frova (frovatriptan) in North America.

This transaction, which Endo first announced on July 14, 2004, was subject to certain closing conditions, including clearance under the Hart- Scott-Rodino Antitrust Improvements Act of 1976, as amended.

Launched in the US in June 2002, Frova is indicated for the acute treatment of migraine headaches in adults. Net sales of Frova in the US were $37.5 million in 2003. Endo will begin its commercial efforts for Frova immediately.